These concepts have recently been highlighted by the new guidelines on diabetic kidney disease (DKD), which recommend treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for CKD patientswith diabetes and albuminuria. This evidence concerns the gene ACE and diabetic kidney disease.